You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm aims to launch an early-access program by the end of the year, followed by a second white paper before the JP Morgan Healthcare Conference in January.
The startup aims to combine its microfluidic platform with a circulating tumor DNA-based assay offered by a potential partner and launch the test by 2022.
The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness.
The firm is engaged in multiple clinical validation trials and aims to raise more than $100 million to launch its Helio Liver Test in the US early next year.
Startup Prophet Genomics plans to commercialize the assay, dubbed Urine Exfoliated Cells Copy Number Aberration Detector, for early detection and monitoring of patients.
The firm said that it has secured coverage for about 100 million lives for its targeted NGS liquid biopsy test in the US between Medicare and private payors.
Recently presented data confirm prior findings that Agendia's MammaPrint may help doctors decide whether to limit tamoxifen treatment in certain patients.
The team published data on Monday highlighting its microfluidic chip's ability to help predict the clinical outcomes of glioblastoma patients.
The London-based firm hopes to also show the clinical utility of its KidneyIntelX assay for predicting the risk of the patients' progressive kidney decline.
Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians.